CCR-sponsored sub-saharan africa multi-site trial support
Ended Awarded Last action
- Contract number
- 75N91023F00007
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,504,608
Award facts
- Contract value 24% obligated
-
- $1,504,608.00 Current, with exercised options
- $6,252,374.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Supplemental Agreement for work within scope | $191,043 | |
| Original award | $1,313,565 |
About this award
This federal contract award, valued at $6,252,374.00, was issued by the National Cancer Institute (NCI) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The award is for the "CCR-SPONSORED SUB-SAHARAN AFRICA MULTI-SITE TRIAL SUPPORT" and has an ultimate completion date of July 16, 2028.
Leidos Biomedical Research Inc. is a Federally Funded Research and Development Center (FFRDC) contractor for the NCI, providing a range of biomedical research and facilities support services. This award does not have a set-aside designation. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type. Leidos Biomedical Research Inc. has supported various research efforts across disease areas, including cancer, HIV/AIDS, influenza, COVID-19, and gene therapy, through its federal contract awards.
Quick answers
Who was awarded contract 75N91023F00007?
75N91023F00007 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on July 28, 2023.
How much is contract 75N91023F00007 worth?
The government has obligated $1,504,608 on 75N91023F00007. Its potential value, with all options, is $6,252,374.
Is contract 75N91023F00007 an order under another contract?
Yes. 75N91023F00007 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00007 competed?
The extent of competition for 75N91023F00007 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award